 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 9 | 1/1 | 返回列表 |
| 查看: 1207 | 回復: 8 | ||
[求助]
求助，謝謝
|
|
Description: This patent application claims the benefit of priority under 35 U.S.C. §119 of German Patent Application No. 199 55 190.1, filed Nov. 16, 1999. German Patent Application No. 199 55 190.1 is incorporated herein in its entirety by reference. The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for manufacturing these and highly pure, stable, intermediate products. From document PCT/EP99/03212 novel derivatives of 3,3-diphenylproprylamines are known. These are valuable prodrugn for the treatment of urinary incontinence and other spasmodic complaints, which overcome the disadvantage of the active substances available to date, namely inadequate absorption of the active substance by biological membranes or the unfavourale metabolism of these. Furthermore these novel prodrugs have improved pharmacokinetic characteristics compared with Oxybutynin and Tolterodin. Preferred compounds from the group of these novel derivatives of 3,3-diphenylpropylarines are esters of aliphatic or aromatic carboxylic acids with the general formula A referred to below in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl or unsubstituted or substituted phenyl. These can occur in their optical isomers form as racemic mixtures and in the form of their individual enantiomers. Compounds with the structure of formula A do, however, have low solubility in water. This restricts their oral bioavailability. Finally, monoesters of the structure, as shown in formula A, have a tendency towards intermolecular transesterification. During long periods of storage, therefore, as the content of the compounds with the structure of general formula A drops an increase in diesters and free diol can be detected. Basically salts of the compounds of general formula A can be obtained if solutions of the compounds of formula A (base component) are purified with solutions of acids in suitable solvents, but the salts obtained in the form of solid matter can prove to be altogether amorphous and/or hygroscopic and cannot be directly crystallized from the normal solvents either. Such salts have inadequate chemical stability to be galenically processed as valuable pharmaceutically active substances. Surprisingly, it has now been found that the abovementioned disadvantages can be avoided if compounds with the structure of general formula A, once they have been prepared under a special reaction process, are converted with a physiologically compatible inorganic or organic acid with general formula H-X, in which − X represents the respective acid residue, into their respective salt with general formula I. The problem for the present invention is therefore to provide highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, that avoid the stated disadvantages and are well suited to use in pharmaceutical-technical formulations and can be processed into these. A further problem for the present invention is to provide a method for manufacturing such highly pure, crystalline, stable compounds in the form of their salts, as well as highly pure, stable intermediate products. The final problem for the invention is to provide a method for manufacturing the abovementioned compounds with which a high yield of the products of the process and the respective intermediate products can be obtained chemo- or regioselectively. This problem is solved in that highly pure, crystalline, stable compounds of the 3,3-diphenylpropylamines in the form of their salts with general formula I are provided, in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, substituted or unsubstituted phenyl and X − is the acid residue of a physiologically compatible inorganic or organic acid. In accordance with a design of the invention the salts of general formula I can contain the respective acid residue X − of the acids mentioned below: • o hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(−  -malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(−-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid. In accordance with a further design form of the invention R-configured compounds with general formula 2 are provided in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, substituted or unsubstituted phenyl and X − is the acid residue of a physiologically compatible inorganic or organic acid. In accordance with an advantageous design form of the invention the compounds in the form of their salts of general formula 2 can contain the respective acid residue X − of the acids mentioned below: • o hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(− -malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(−-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid. Preferred compounds of the present invention are the salts • o R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hy droxymethylphenylisobutyrate ester hydrogen fumarate and o R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hy droxymethylphenylisobutyrate ester hydrochloride hydrate. Furthermore, compounds are preferred in which R stands for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-(1-cyclo-propyl-methanoyloxy)-phenyl, 4-(1-cyclobutyl-methanoyloxy)-phenyl, 4-(1-cyclohexyl-methanoyloxy)-phenyl or 4-(2,2-dimethyl-propanoyloxy)-phenyl and X denotes chloride. Particular preference is for [(R)-3-(2-{1-[4-(1-cyclopropyl-methanoyloxy)-phenyl]-methano yloxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl- ammonium chloride, [(R)-3-(2-{1-[4-(1-cyclobutyl-methanoyloxy)-phenyl]-methanoy loxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium chloride, [(R)-3-(2-{1-[4-(1-cyclohexyl-methanoyloxy)-phenyl]-methanoy loxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium chloride, [(R)-3-(2-{1-[4-(2,2-dimethyl-propanoyloxy)-phenyl]-methanoy loxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium chloride, {(R)-3-[2-(1-cyclopropyl-methanoyloxy)-5-hydroxymethyl-pheny l]-3-phenyl-propyl}-diisopropyl-ammonium chloride, {(R)-3-[2-(1-cyclobutyl-methanoyloxy)-5-hydroxymethyl-phenyl ]-3-phenyl-propyl}-diisopropyl-ammonium chloride, {(R)-3-[2-(1-cyclopentyl-methanoyloxy)-5-hydroxymethyl-pheny l]-3-phenyl-propyl}-diisopropyl-ammonium chloride and {(R)-3-[2-(1-cyclohexyl-methanoyloxy)-5-hydroxymethyl-phenyl ]-3-phenyl-propyl}-diisopropyl-ammonium chloride. In the compounds of the present invention the expression “alkyl” preferably stands for a straight-chain or branched-chain hydrogen group with between 1 and 6 C-atoms. Special preference is for methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl and hexyl. The expression “cycloalkyl” designates cyclical hydrogen groups, that have between 3 and 10 hydrogen atoms, that may also contain suitable substitutes in place of the hydrogen atoms. The expression “phenyl” designates a —C 6 H 5 -group that may be substituted or unsubstituted. Suitable substitutes can be, for example, alkyl, alkoxy, halogen, nitro and amine. The expression “alkoxy” has, with respect to the alkyl component, the same meaning as already given above for “alkyl”. Suitable halogens are fluorine, chlorine, bromine and iodine atoms The present invention also includes methods for manufacturing the compounds in accordance with the invention of general formula I as well as valuable intermediate products. The method is characterised by chemo- and regioselectivity. Compounds of General Formula I in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, substituted or unsubstituted phenyl and X − is the acid residue of a physiologically compatible inorganic or organic acid, are that • o a) a compound of formula III is split with a hydrogenation agent to form a compound of formula V whereupon o b) the compound of formula V so obtained is converted with agent, in order to give a compound of formula VI which o c) is converted with an acylation agent, in order to obtain of formula A in which R has the significance stated above, which d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula I in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, unsubstituted or substituted phenyl and X− is the acid residue of a physiologically compatible inorganic or organic acid. In accordance with the invention, for the manufacture of the compounds of general formula I hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(− -malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(−-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used. In accordance with an advantageous further development of the invention a method for the manufacture of R-configured compounds of the general formula 2 is described, in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, substituted or unsubstituted phenyl and X − is the acid residue of a physiologically compatible inorganic or organic acid, in that • o a) a compound of formula 3 is split with a hydrogenation agent to form a compound of formula 5 whereupon o b) the compound of formula 5 so obtained is converted with a reducing agent, in order to give a compound of formula 6 which o c) is converted with an acylation agent, in order to obtain a compound of formula 1 in which R has the significance stated above, which o d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula 2 in which R denotes C 1 -C 6 -alkyl, C 3 -C 10 -cycloalkyl, unsubstituted or substituted phenyl and X− is the acid residue of a physiologically compatible inorganic or organic acid. Advantageously in order to obtain compounds of general formula 2, in accordance with the method hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(− -malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(−-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+) -glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used. Particular advantageously, on the basis of the crystalline R-(− -4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)be nzoic acid methyl ester, the highly pure, crystalline intermediate product R-(−-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzo ic acid methyl ester is prepared, which is reduced to R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylp henol, is finally acylated in a suitable manner and is then converted with a physiologically compatible inorganic or organic acid under spontaneous crystallization to the respective highly pure, crystalline, stable salt. Depending on the acid chloride used, compounds of general formula 1 are obtained, in which R denotes C 1 -C 6 -alkyl, in particular isopropyl, C 3 -C 10 -cycloalkyl or unsubstituted or substituted phenyl. |
回復此樓» 猜你喜歡
材料/農業(yè)專業(yè)，07/08開頭均可，過線就行
已經有4人回復
-
327求調劑
已經有5人回復
-
361求調劑
已經有3人回復
-
一志愿中南大學化學學碩0703總分337求調劑
已經有5人回復
-
一志愿北京化工大學 070300 學碩 336分 求調劑
已經有6人回復
-
材料專業(yè)求調劑
已經有10人回復
-
341求調劑(一志愿湖南大學070300)
已經有5人回復
-
0854 考研調劑 招生了！AI 方向
已經有15人回復
-
384求調劑
已經有6人回復
-
生物學學碩求調劑
已經有4人回復
meng851124
木蟲 (正式寫手)
- 應助: 0 (幼兒園)
- 金幣: 1987.5
- 帖子: 536
- 在線: 68.3小時
- 蟲號: 855774
- 注冊: 2009-09-24
- 性別: GG
- 專業(yè): 高分子合成化學
2樓2010-04-23 22:55:14
very小強
新蟲 (初入文壇)
- 應助: 0 (幼兒園)
- 金幣: 155
- 帖子: 7
- 在線: 1.8小時
- 蟲號: 875405
- 注冊: 2009-10-17
- 性別: GG
- 專業(yè): 藥物學其他科學問題
3樓2010-04-24 15:31:48
FePt
木蟲 (正式寫手)
- 應助: 0 (幼兒園)
- 金幣: 1851
- 散金: 25
- 帖子: 717
- 在線: 284.8小時
- 蟲號: 502966
- 注冊: 2008-02-15
- 專業(yè): 電工材料特性及其應用
4樓2010-04-24 16:36:07
melody-yhl
木蟲 (著名寫手)
職業(yè)寫手
- 翻譯EPI: 9
- 應助: 0 (幼兒園)
- 金幣: 2351.2
- 紅花: 2
- 帖子: 1124
- 在線: 101.2小時
- 蟲號: 311276
- 注冊: 2006-12-25
- 性別: MM
- 專業(yè): 生物化工與食品化工
5樓2010-04-24 17:44:57
melody-yhl
木蟲 (著名寫手)
職業(yè)寫手
- 翻譯EPI: 9
- 應助: 0 (幼兒園)
- 金幣: 2351.2
- 紅花: 2
- 帖子: 1124
- 在線: 101.2小時
- 蟲號: 311276
- 注冊: 2006-12-25
- 性別: MM
- 專業(yè): 生物化工與食品化工
6樓2010-04-24 17:49:12
7樓2010-04-24 22:54:20
davidyanli
銅蟲 (初入文壇)
- 應助: 0 (幼兒園)
- 金幣: 68
- 紅花: 1
- 帖子: 8
- 在線: 2.8小時
- 蟲號: 1005134
- 注冊: 2010-04-25
- 性別: GG
- 專業(yè): 有機合成
8樓2010-05-19 00:16:48
davidyanli
銅蟲 (初入文壇)
- 應助: 0 (幼兒園)
- 金幣: 68
- 紅花: 1
- 帖子: 8
- 在線: 2.8小時
- 蟲號: 1005134
- 注冊: 2010-04-25
- 性別: GG
- 專業(yè): 有機合成
【答案】應助回帖
★ ★ ★
wypward(金幣+3):這是谷歌翻譯的吧！但還是謝謝參與 2010-05-24 09:22:36
wypward(金幣+3):這是谷歌翻譯的吧！但還是謝謝參與 2010-05-24 09:22:36
|
描述: 該專利申請要求優(yōu)先權的35歲以下的編119德國中華民國專利申請案號(55 190.1、歸檔。199年11月16日。德國的專利申請?zhí)?90.1 199 55一同被整合,以供參考。 本發(fā)明關切的高純度、水晶、穩(wěn)定的混合物,3-diphenylpropylamines小說的衍生3的形式的一種方法,他們的鹽、高純度,生產這些、穩(wěn)定、中間產品。 從文件EP99/03212 PCT / 3,3-diphenylproprylamines衍生物的小說是眾所周知的。 這些都是珍貴的prodrugn治療性尿失禁和其他船上投訴,克服不利的活性物質可到目前為止,即不足的活性物質的吸收由生物膜或unfavourale代謝。 而且這些小說已經改善代謝特點熱點和Tolterodin Oxybutynin相比。 優(yōu)先化合物的這些小說中有3個,3-diphenylpropylarines衍生的脂肪或芳香羧酸酯酸與一般公式是指以下 在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl或unsubstituted或取代苯。這些可以發(fā)生在他們的光學異構體用表格的形式混合物和個人對映體。 化合物的結構,然而,一個做公式水溶性較低。這種限制他們的口腔生物利用度。 最后,使結構,如圖配方,有一間以傾向。在長期貯存,因此,為內容的化合物的結構,增加的一般表達式,在其中一個滴醇能被探測到,免費。 基本上鹽的通用公式的化合物是可以解決的公式的化合物(組件基)的純化解酸在適當?shù)娜軇?但是鹽的形式獲得固體物質不能證明是共晶和/或吸濕性,不能直接從正常的溶劑結晶。這樣的鹽不足的化學穩(wěn)定性是galenically處理為價值”活性物質。 令人驚訝的是,它現(xiàn)在已經發(fā)現(xiàn)上述缺點可以避免的化合物的結構一般公式,一旦他們已經準備下一個特別的反應過程,為有生理兼容的無機或有機酸和一般公式,H-X−X代表各自的酸性渣,為各自的鹽與一般的公式。 本發(fā)明的問題,因此提供的高純度、水晶、穩(wěn)定的混合物,3-diphenylpropylamines小說的衍生3的形式,避免了他們的鹽陳述弊端,非常適合用于pharmaceutical-technical配方,可加工成這些。 進一步的問題,本發(fā)明提供一種高純度為制造這樣,水晶,穩(wěn)定化合物的形式的鹽,以及高純度、穩(wěn)定的中間體。 最后的問題是提供了一種方法發(fā)明制造上述化合物和高產的產品的工藝及各自的中間產品可以獲得——或者可以化療。 這個問題已經解決,高純度、水晶、穩(wěn)定化合物的三、3-diphenylpropylamines的鹽的形式與一般公式我, 在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl取代苯、unsubstituted,或者是酸性渣X−的生理兼容的無機或有機酸。 按照設計的一般公式,發(fā)明了鹽,我可以包含了各自的酸性渣X−以下的氨基酸。 • 啊,hydrobromic鹽酸酸、磷酸、硫酸、硝酸、醋酸、丙酸、酸、硬脂酸、馬來酸、富馬酸、草酸琥珀酸、DL-malic酸、L -(−-malic酸、D -(+)-malic酸、DL-tartaric酸、L -(+)-tartaric酸、D -(−-tartaric酸、檸檬酸、天冬氨酸、L -(+)-ascorbic酸、D -(+)-glucuronic酸、2-oxopropionic酸(丙酮酸),furan-2-carboxylic酸(mucic酸)、苯甲酸、4-hydroxybenzoic酸、salicyclic酸、vanillic酸、4-hydroxycinammic酸、沒食子酸、馬尿酸(N-benzoyl-glycine),aceturic酸(N-aectylglycine),phloretinic酸(3 -(4-hydroxyphenyl)-propionic酸)、鄰苯二甲酸、四種羧酸或orotic酸。 依照進一步設計的一般公式R-configured發(fā)明和2個被提供 在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl取代苯、unsubstituted,或者是酸性渣X−的生理兼容的無機或有機酸。 依照一個有利的設計形式的發(fā)明的形式的化合物的一般公式的鹽可容納2×−各自的酸性渣酸下面提到: • 啊,hydrobromic鹽酸酸、磷酸、硫酸、硝酸、醋酸、丙酸、酸、硬脂酸、馬來酸、富馬酸、草酸琥珀酸、DL-malic酸、L -(−-malic酸、D -(+)-malic酸、DL-tartaric酸、L -(+)-tartaric酸、D -(−-tartaric酸、檸檬酸、天冬氨酸、L -(+)-ascorbic酸、D -(+)-glucuronic酸、2-oxopropionic酸(丙酮酸),furan-2-carboxylic酸(mucic酸)、苯甲酸、4-hydroxybenzoic酸、salicyclic酸、vanillic酸、4-hydroxycinammic酸、沒食子酸、馬尿酸(N-benzoyl-glycine),aceturic酸(N-aectylglycine),phloretinic酸(3 -(4-hydroxyphenyl)-propionic酸)、鄰苯二甲酸、四種羧酸或orotic酸。 本發(fā)明的優(yōu)先化合物的鹽 • o R -(+)- 2 -(3-diisopropylamino-1-phenylpropyl)-4-hy droxymethylphenylisobutyrate富氫酯和 o R -(+)- 2 -(3-diisopropylamino-1-phenylpropyl)-4-hy droxymethylphenylisobutyrate酯鹽酸鹽保濕。 再者,化合物的首選,cyclobutyl R代表cyclopropyl,cyclopentyl,cyclohexyl、4 -(2)-phenyl 1-cyclo-propyl-methanoyloxy,4 -(2)-phenyl 1-cyclobutyl-methanoyloxy,4 -(2)-phenyl 1-cyclohexyl-methanoyloxy或4 -(2)-phenyl 2-dimethyl-propanoyloxy和X表示。 特別偏愛是[(R)- 3 -(2 - { 1 - 4 -(1-cyclopropyl-methanoyloxy)-phenyl]-methano yloxy } -5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl -氯化銨,[(R)- 3 -(2 - { 1 - 4 -(1-cyclobutyl-methanoyloxy)-phenyl]-methanoy loxy } -5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium氯、[(R)- 3 -(2 - { 1 - 4 -(1-cyclohexyl-methanoyloxy)-phenyl]-methanoy loxy } -5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium氯、[(R)- 3 -(2 - { 1 - 4 -(2)-phenyl]-methanoy 2-dimethyl-propanoyloxy loxy } -5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-a mmonium氯、{(R)- 3 -(2 -(1-cyclopropyl-methanoyloxy)-5-hydroxymethyl-pheny]-3-phenyl-propyl } -diisopropyl-ammonium氯、{(R)- 3 -(2 -(1-cyclobutyl-methanoyloxy)-5-hydroxymethyl-phenyl]-3-phenyl-propyl } -diisopropyl-ammonium氯、{(R)- 3 -(2 -(1-cyclopentyl-methanoyloxy)-5-hydroxymethyl-pheny]-3-phenyl-propyl } -diisopropyl-ammonium氯和{(R)- 3 -(2 -(1-cyclohexyl-methanoyloxy)-5-hydroxymethyl-phenyl]-3-phenyl-propyl } -diisopropyl-ammonium氯。 在這個化合物的本發(fā)明表達"烷基“最好是代表了一種straight-chain或branched-chain氫集團在1到6 C-atoms。特殊偏好、乙酸乙酯、醋酸丙對甲基異丙酯、醋酸異丁,,,pentyl和hexyl。表達" cycloalkyl”指明周期性氫團體,有3 - 10個氫原子,也可能包含了合適的替代品代替氫原子。 表達"苯基”指明了-C 6小時5 -group可替代或unsubstituted。合適的替代品,例如、醇酸、氧、鹵素,硝基和三聚氰胺。表達"中",就烷基的組成部分,已給以上含義相同的“烷基”。適合有氟、氯離子、鹵素溴碘原子 本發(fā)明也包括方法生產化合物的發(fā)明,按照一般公式我以及寶貴的中間體。 這個方法的特點是化學-和區(qū)域選擇性。 我的一般公式 在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl取代苯、unsubstituted,或者是酸性渣X−的生理兼容的無機或有機酸,是那樣 • 一)的化合物啊。配方 用一個分裂形成一種化合物加氫劑的配方V嗎 于是 o b)的轉換公式,用了V的代理人,以給一組配方VI , o c)轉換為原料,經酰化劑,以為了得到的公式 在上述的意義[j]. d),與生理兼容無機物轉化為酸或有機化合物的形成 在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl,unsubstituted或取代苯和X−是酸性渣的生理兼容的無機或有機酸。 依照這項發(fā)明,為制造的化合物的通用公式我鹽酸、hydrobromic酸、磷酸、硫酸、硝酸、醋酸、丙酸、酸、硬脂酸、馬來酸、富馬酸、草酸琥珀酸、DL-malic酸、L -(−-malic酸、D -(+)-malic酸、DL-tartaric酸、L -(+)-tartaric酸、D -(−-tartaric酸、檸檬酸、天冬氨酸、L -(+)-ascorbic酸、D -(+)-glucuronic酸、2-oxopropionic酸(丙酮酸),furan-2-carboxylic酸(mucic酸)、苯甲酸、4-hydroxybenzoic酸、salicyclic酸、vanillic酸、4-hydroxycinammic酸、沒食子酸、馬尿酸(N-benzoyl-glycine),aceturic酸(N-aectylglycine),phloretinic酸(3 -(4-hydroxyphenyl)-propionic酸)、鄰苯二甲酸、四種羧酸或orotic酸。 依照一個有利的進一步發(fā)展的發(fā)明了一種化合物,R-configured制造的一般公式,二是描述, 在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl取代苯、unsubstituted,或者是酸性渣X−的生理兼容的無機或有機酸,在那 • 一個復合的阿三級方程式 用一個分裂形成一種化合物加氫劑的配方 于是 o b)的轉換公式5所以取得與還原劑,為了給一個公式 , o c)轉換為原料,經�；瘎�,以為了獲得了一級方程式 在上述的意義[j],它 阿d)轉化為有生理兼容的無機或有機酸形成化合物的配方2 在R代表C 1 -C 6 -alkyl、C 3 -C 10 -cycloalkyl,unsubstituted或取代苯和X−是酸性渣的生理兼容的無機或有機酸。 為了獲得成分資料庫的通用公式,依照《中華人民共和國hydrobromic鹽酸、酸法、磷酸、硫酸、硝酸、醋酸、丙酸、酸、硬脂酸、馬來酸、富馬酸、草酸琥珀酸、DL-malic酸、L -(−-malic酸、D -(+)-malic酸、DL-tartaric酸、L -(+)-tartaric酸、D -(−-tartaric酸、檸檬酸、天冬氨酸、L -(+)-ascorbic酸、D -(+)-glucuronic酸、2-oxopropionic酸(丙酮酸),furan-2-carboxylic酸(mucic酸)、苯甲酸、4-hydroxybenzoic酸、salicyclic酸、vanillic酸、4-hydroxycinammic酸、沒食子酸、馬尿酸(N-benzoyl-glycine),aceturic酸(N-aectylglycine),phloretinic酸(3 -(4-hydroxyphenyl)-propionic酸)、鄰苯二甲酸、四種羧酸或orotic酸。 特定資料庫的基礎上,-4-benzyloxy-3水晶R -(− 是nzoic——(3-diisopropylamino-1-phenyl-propyl酸甲酯、高純度、中間產品的R -(3 -(3-diisopropylamino-phenyl-propyl−-4-hydroxy-benzo ic酸甲酯制備,降至R -(+)- 2 -(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylp henol,終于在一個合適的方式、�；蜕砩先缓筠D換兼容無機或有機酸下結晶的自發(fā)的高純度、水晶、穩(wěn)定的鹽。根據(jù)酸氯化合物的一般公式,1, 在R代表C 1 -C 6 -alkyl,尤其是異丙醇、丙三-C 10 -cycloalkyl或unsubstituted或取代苯。 |
9樓2010-05-19 00:21:55
相關版塊跳轉
我要訂閱樓主 木子8210 的主題更新
| 9 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 材料專碩英一數(shù)二306 +8 | z1z2z3879 2026-03-18 | 8/400 |
|
|---|---|---|---|---|
|
|
[考研] 085600材料與化工調劑 +6 | A-哆啦Z夢 2026-03-23 | 11/550 |
|
|
[考研] 一志愿武理材料工程348求調劑 +6 | ￣^￣゜汗 2026-03-19 | 9/450 |
|
|
|
[考研] 生物學一志愿985，分數(shù)349求調劑 +6 | zxts12 2026-03-21 | 9/450 |
|
|
|
[考研] 328求調劑，英語六級551，有科研經歷 +7 | 生物工程調劑 2026-03-17 | 12/600 |
|
|
|
[考研] 工科0856求調劑 +5 | 沐析汀汀 2026-03-21 | 5/250 |
|
|
|
[考研] 08工學調劑 +7 | 用戶573181 2026-03-20 | 11/550 |
|
|
|
[考研] 284求調劑 +6 | Zhao anqi 2026-03-22 | 6/300 |
|
|
|
[考研] 276求調劑 +3 | YNRYG 2026-03-21 | 4/200 |
|
|
|
[考研] 280分求調劑 一志愿085802 +4 | PUMPT 2026-03-22 | 7/350 |
|
|
|
[考研] 289求調劑 +7 | 懷瑾握瑜l 2026-03-20 | 7/350 |
|
|
|
[考研] 280求調劑 +11 | 咕嚕曉曉 2026-03-18 | 12/600 |
|
|
|
[考研] 332求調劑 +4 | ydfyh 2026-03-17 | 4/200 |
|
|
|
[考研] 南京大學化學376求調劑 +3 | hisfailed 2026-03-19 | 6/300 |
|
|
|
[考研] 材料學求調劑 +4 | Stella_Yao 2026-03-20 | 4/200 |
|
|
|
[論文投稿]
申請回稿延期一個月，編輯同意了。但系統(tǒng)上的時間沒變，給編輯又寫郵件了，沒回復
 10+3
|
wangf9518 2026-03-17 | 4/200 |
|
|
|
[考研] 288求調劑，一志愿華南理工大學071005 +5 | ioodiiij 2026-03-17 | 5/250 |
|
|
|
[考研] 一志愿福大288有機化學，求調劑 +3 | 小木蟲200408204 2026-03-18 | 3/150 |
|
|
|
[考研] 材料，紡織，生物（0856、0710），化學招生啦 +3 | Eember. 2026-03-17 | 9/450 |
|
|
|
[考研] 有沒有道鐵/土木的想調劑南林，給自己招師弟中～ +3 | TqlXswl 2026-03-16 | 7/350 |
|